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Introduction
Several  European  epidemiologic  studies  reveal  the  cata-
strophic  and  interrelated  complications  of  cardiorenal  failure 
in the diabetic population (DREAM,1 LIRICO,2 HOPE3 and 
FRAMINGHAM4). However, in the United States the clinical 
manifestation and significance of the combined effects of cardio-
vascular and renal disease remain underappreciated. Currently, 
the number of diabetics in the United States is estimated at 23.4 
million people or 7.8% of entire population.5,6 Despite the numer-
ous pathologies associated with type II diabetes, nearly 2/3rds of 
all diabetic patients die of heart failure.7 However, the contribu-
tion of renal dysfunction to the onset of myocardial dysfunction 
in diabetes, independent of ischemic disease, remains unknown.
Numerous studies investigating the effects of Type II dia-
betes on the heart have used the Zucker diabetic fatty (ZDF) 
rat model.8 Likewise, investigators examining diabetes-induced 
nephropathy have also employed the ZDF rat.9 Although there 
is an association between decreased renal function and increased 
cardiovascular morbidity/mortality,10,11 few studies have exam-
ined the correlative onset of each of these disease states and the 
impact they have on the overall progression of pathologic changes 
in  individual  organ  systems.12,13  Moreover,  the  time  points 
selected in various separate studies on the heart and kidney in 
diabetic rats differ significantly, which further confounds the 
ability to determine the relationship between these pathologies. 
To address the temporal relationship between renal and cardio-
vascular pathology in diabetes, this study examines left ventricu-
lar (LV) remodeling and systolic/diastolic functional parameters 
and renal morphology and function in the same animals at two 
time points, 16 and 36 weeks of age. These time points were cho-
sen as they best correspond to the early (14–17 weeks of age) and 
later stage (24–37 weeks of age) ranges of animal ages used in 
previous studies, focused on either cardiac or renal pathophysiol-
ogy.13-18 We hypothesize the ZDF animal model of type II dia-
betes will display systolic and diastolic dysfunction at the earlier 
time point prior to development of renal pathology. Whereas we 
believe there will be significant loss of systolic and diastolic ven-
tricular function at 36 weeks of age, which corresponds to the 
severity of renal pathology.
Results
Comparison of body and LV weights between lean control and 
ZDF rats. By 16 weeks of age ZDF animals weighed signifi-
cantly more than their age-matched LC group. However, at 36 
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and LC at 36 weeks (Table 2). The fact that stroke volume was 
increased at the earlier, but not the later time point, is signifi-
cant as this could indicate that the intrinsic stretch response of 
the heart (Frank-Starling) was an adaptational response while 
the ventricle continued to remodel. Ejection fraction which was 
43% at 16 weeks decreased to 24% in the 36 week ZDF group. 
Overall, these results indicate that there was progressive dilata-
tion of the LV chamber.
Neither  maximum  nor  minimum  first  derivative  of  LV 
pressure (dP/dt; an indicator of myocardial contractility) was   
different between groups at either time point. The maximum and 
minimum first derivative of LV volume (dV/dtmax = left ventricu-
lar ejection rate during systole, and dV/dtmin = peak rate of passive 
diastolic filling of the left ventricle, respectively) were higher in 
the 16-week-old ZDF versus LC. There was a significant increase 
in maximal and minimal dV/dt between 36-week-old ZDF and 
age-matched LC hearts (Table 2). Additionally, there was a trend 
(p = 0.09) toward an increase in optimal volume for maximum 
dP/dt (Vol@dP/dt max) in the ZDF group at 16 weeks; this 
increase became statistically significant at 36 weeks compared to 
LC (p ≤ 0.05). These changes in volume @ dP/dt suggest that in 
order to maintain contractility the heart has adapted to optimize 
actin and myosin filament overlap enabling more cross bridge 
weeks there was a marked reduction of body weight in the ZDF 
group (Table 1). Blood glucose was significantly elevated in the 
ZDF group compared to LC at both 16 and 36 weeks of age. 
LV mass was significantly decreased in the ZDF groups at both 
time points compared to age matched LC. These trends were also   
evident when normalized to tibial lengths.
Left  ventricular  morphology  and  functional  assessment. 
Table 2 details ventricular structural and functional parameters 
for all groups. Mean arterial blood pressure was not significantly 
different between ZDF and LC at 16 weeks of age (113 ± 11 vs. 
102 ± 4 mmHg; ZDF vs. LC) or at 36 weeks of age (108 ± 6 mm 
vs. 113 ± 5 Hg; ZDF vs. LC respectively). End diastolic volume 
(EDV)  in  ZDF  rats  was  increased  by  16%  at  16  weeks  and 
increased by 37% at 36 weeks of age relative to age-matched 
LC. The change in chamber volume was mirrored by a signifi-
cant increase in end diastolic pressure (EDP) (42% increase) at   
36 weeks of age which was not seen at 16 weeks. Additionally, 
at 36 weeks end systolic volume (ESV) was markedly increased 
(27%) compared to age matched LC, but, again, this change in 
ESV was not evident at 16 weeks of age. No difference in heart 
rate or cardiac output was evident between any of the groups; 
however  stroke  volume  which  was  significantly  increased  in 
the 16 week ZDF group was no longer different between ZDF 
Table 1. Comparison of whole body, LV and kidney weights in LC and ZDF rats at 16 and 36 weeks of age
Body weight  
(gm)
LV weight  
(mg)
Left kidney weight  
(mg)
Right kidney weight  
(mg)
Blood glucose  
(mg/dl)
16 weeks of age
Lean Control 329 ± 25 917 ± 47 1300 ± 95 1296 ± 64 105 ± 15
ZDF 413 ± 31* 850 ± 50* 1939 ± 109* 1960 ± 250* 545 ± 52*
36 weeks of age
Lean Control 456 ± 11 920 ± 32 1271 ± 94 1282 ± 85 105 ± 7
ZDF 358 ± 39* 796 ± 80* 1864 ± 84* 1933 ± 222* 392 ± 29*
all values are reported as mean ± sD. *denotes p ≤ 0.05 compared to age-matched LC rats.




























@ Min & 
Max  
dP/dt (µl)
Min & Max 
dV/dt 
(µl/sec)
16 weeks of 
age
Lean Control 282 ± 10 121 ± 3 9 ± 1 196 ± 22 306 ± 23 31 ± 5 110 ± 16 206 ± 25 
301 ± 24
-2134 ± 400  
2778 ± 330
ZDF 282 ± 35 117 ± 16 10 ± 1 200 ± 13 355 ± 4* 44 ± 7 155 ± 16* 227 ± 17 
364 ± 19*
-2268 ± 372 
3251 ± 284
36 weeks of 
age
Lean Control 265 ± 10 124 ± 5 7 ± 1 299 ± 16 367 ± 12 36 ± 3 138 ± 13 238 ± 19 
350 ± 12
-3267 ± 200 
3750 ± 540
ZDF 235 ± 10 125 ± 8 10 ± 1* 380 ± 34* 504 ± 34* 29 ± 2 123 ± 5 394 ± 35* 
497 ± 35*
-2643 ± 325* 
2819 ± 260*
Values are presented as mean ± seM. *denotes p < 0.05 versus age-matched LC rats. n ≥ 6 per group. dP/dt = an indicator of myocardial contractil-
ity (maximum or minimum first derivative of LV pressure) dV/dtmax = left ventricular ejection rate during systole, and dV/dtmin = peak rate of passive 
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formation during contraction. Lastly, we analyzed the time con-
stant of LV pressure decay, Tau, as a measurement of LV relax-
ation according to Weisfeldt et al.19,20 Tau was increased in the 
ZDF group at both 16 and 36 weeks, compared to age-matched 
LC groups (22 ± 1 vs. 13 ± 0.4 msec, p ≤ 0.01, at 16 weeks; and 
16 ± 0.5 vs. 13 ± 0.5 msec, p ≤ 0.05, at 36 weeks). Collectively, 
these overall changes in LV chamber morphology and function 
are characteristic of diastolic cardiomyopathy in diabetic patients, 
and also of diastolic heart failure which is an emerging clinical 
manifestation in heart failure patients.
Renal structural and functional assessment. As shown in 
Table 1, both left and right kidney weights were appreciably 
increased in the ZDF group, compared to LC, as early as 16 
weeks of age. At 36 weeks kidney weights were still significantly 
increased above age-matched LC but not different from values 
seen at 16 weeks. Water intake was increased by six-fold at 16 
weeks and remained elevated at 36 weeks of age in ZDF rats rela-
tive to LC. Urine output in the ZDF group was increased eight-
fold as early as 10 weeks of age (Fig. 1). By 16 weeks urine output 
was elevated 20-fold above LC and remained at this level at 36 
weeks of age. Figure 2 illustrates the morphological changes in 
the kidneys from ZDF animals. Of these animals, 14% showed 
signs  of  moderate  levels  of  hydro-
nephrosis at 16 weeks of age (Table 
3). At 36 weeks of age, evidence of 
a shift to mostly mild to moderate 
hydronephrosis  was  also  apparent 
in the lean control group. However, 
the 36-week-old ZDF group exhib-
ited  predominately  moderate  to 
severe  signs  of  hydronephrosis   
(Table  3,  Fig.  2).  Hyperfiltration 
caused by diabetes induced vasodi-
latation  may  significantly  contrib-
ute to the progression of this form 
of obstructive uropathy in the ZDF 
rat.21
Excretion  of  urinary  albumin 
was  unchanged  at  16  weeks,  rela-
tive to controls, but was markedly increased at 24 weeks and 
progressed  further  at  36  weeks  (Fig.  3).  Urinary  creatinine   
levels  were  also  significantly  decreased  at  all  time  points   
relative to LC purportedly because of urine dilution. The ratio 
of urinary albumin to creatinine, an indicator of microalbu-
minuria, remained constant in the lean control animals, but 
increased significantly in ZDF rats as early as 10 weeks of age, 
and significantly increased further between 10 and 36 weeks 
in ZDF rats (Table 4). Lastly, we performed correlation analy-
sis by linear regression between cardiac parameters (e.g., vol-
ume and function) and renal function parameters. Significant   
correlation was found in the 36 week old ZDF group between 
urinary albumin and stroke work  (r2 value = 0.94, p = 0.02). 
Moreover,  urinary  creatinine  was    positively  correlated  with 
cardiac output in the 36 weeks old ZDF group (r2 value = 0.67, 
p = 0.04).
Figure 1. Comparison of 24 hour urine output in Lean Control and 
Zucker diabetic fatty (ZDF) rat kidneys at 10, 16, 24 and 36 weeks of age. 
Urine output is significantly increased in ZDF animals as early as 10 weeks 
of age and remains markedly increased at all time points relative to lean 
controls. Values are mean ± sD. *denotes p ≤ 0.01 versus age matched lean 
control.
Figure 2. Representative images of hydronephrosis in Lean Control (LC) and Zucker diabetic fatty (ZDF) 
rats at 16 and 36 weeks of age. Kidneys were cut across the cross-sectional axis of the hillar region. Evi-
dence of progression of morphologic changes is seen in both LC and ZDF kidneys from 16 to 36 weeks of 
age with hydronephrosis being more severe in the diabetic animals.
Table 3. scoring and distribution of hydronephrosis in lean control 















Normal 5 (71) 1 (14) 0 (0) 0 (0)
Mild 2 (29) 5 (71) 2 (28) 1 (10)
Moderate 0 1 (14) 5 (77) 6 (60)
Severe 0 0 0 (0) 3 (30)
Briefly, kidney sections were assigned a value of either; (0) minimal or 
no spacing between the papilla and calyx, (1) definitive but mild calyceal 
spacing with normal papillary shape, (2) calyceal dilatation and compres-
sion of the papilla, and (3) extreme distension of the calyx, compaction 
of the lateral cortex and severe papillary dilatation. Values are presented 
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pressure  (minimum  and  maximum  dP/dt)  were  decreased  in 
ZDF animals compared to LC, whereas multiple indices of LV 
systolic function and compliance were not significantly different. 
Because of the limited amount of simultaneous/parallel informa-
tion on the development of diabetic cardiomyopathy and renal 
pathology, we sought to investigate the kinetics of development 
of changes in left ventricular and renal morphology and function 
in an animal model of type II diabetes.
Left ventricular morphology and functional assessment. We 
observed that significant changes in LV chamber morphology 
occurred in the untreated ZDF animals as a diabetes-induced 
adaptation to maintain overall function. Specifically, type II dia-
betic rats had significantly increased left ventricular end systolic 
and end diastolic volume(s) compared to LC animals as early as 
16 weeks of age. Stroke volume was also significantly increased 
at the same time. Additionally, the rate of volume change in the 
LV as indicated by minimum and maximum first derivative of 
LV volume (dV/dt) was also elevated in the 16-week-old ZDF 
versus age-matched LC. These findings are consistent with the 
previous findings by Fredersdorf et al.23 which demonstrated that 
at 19 weeks of age the ZDF rat exhibited enhanced contractility. 
Ultimately, the response of the heart is to maintain cardiac output 
and thus preserve mean arterial pressure. Initially in other forms 
of heart failure, the stretch of the myocytes due to end diastolic 
volume (also known as preload) seeks to maximize overlap poten-
tial for actin and myosin filaments within the existing sarcomeres 
a phenomenon known as the Frank-Starling mechanism. By this 
means, renal blood flow and glomerular filtration rate would sup-
posedly be able to maintain normal physiologic function at the 
16 weeks of age endpoint as increased systolic blood pressure in 
this model is associated with renal injury.24,25 Chronically, dila-
tation of the LV chamber allows the heart to maintain cardiac 
output by adding sarcomeres (contractile units) in a parallel or in 
series fashion to the preexisting sarcomeres. Eventually, a point 
is reached where the ability of the heart to further compensate is 
exhausted and the contractile force of the muscle becomes inef-
fective and heart begins to fail.26,27 At this stage, ventricular mass 
is no longer increased relative to the enlargement of the cham-
ber volume which is what we observed at the 36 weeks of age 
Discussion
Guyton’s model of cardiorenal syndrome illustrates the patho-
physiologic interconnection between the heart and kidney organ 
systems.22  Due  to  the  interrelated  nature  of  their  function, 
changes in one system (cardiovascular) can catalyze changes in 
the other (renal) which lead to an adverse feedback cycle involving 
neurohormonal, systemic and local inflammatory mechanisms. 
However, the point at which the collective effects of ventricu-
lar and renal dysfunction becomes greater than their individual 
pathologies remains to be elucidated. Clinical studies demon-
strate a strong link between symptomatic heart failure and renal 
dysfunction, but raise questions as to which is the true secondary 
illness.11 A recent study by Marsh et al.12 reported altered diastolic 
relaxation as well as the presence of hydronephrosis in the ZDF 
rat at 14 weeks of age. On the other hand, work by Fredersdorf 
et al.23 investigating insulin’s affect on myocardial morphology 
and function in non insulin dependent diabetes concluded that 
at 19 weeks of age the ZDF rat exhibited LV hypertrophy and 
enhanced contractility as assessed by echocardiography. Schafer 
et al.13 also showed that at 37 weeks of age both glomeruloscle-
rosis and proteinuria were present in the ZDF rat. However, in 
that study, only heart rate and minimum first derivative of LV 
Figure 3. Temporal course of 24 hour urinary 
excretion of albumin from Lean Control (LC) 
& Zucker diabetic fatty (ZDF) rat kidneys at 
10, 16, 24 and 36 weeks of age. Excretion of 
urinary albumin was unchanged at 10 or 16 
weeks of age, relative to LC, but was markedly 
increased at 24 weeks and progressed further 
at 36 weeks relative to LC as well as the 10 
and 16 weeks of age values in the same animals. 
Values are mean ± sD. *denotes p ≤ 0.01 versus 
age matched lean control. †p ≤ 0.01 versus 10 
weeks of age ZDF. #p < 0.05 vs. 24 weeks of 
age ZDF.
Table 4. Urinary excretion of creatinine and albumin by LC & ZDF rats 










8.3 ± 0.5 10.5 ± 
0.5




42 ± 16 47 ± 3 31 ± 1 41 ± 7










Values are mean ± seM. *denotes p ≤ 0.01 versus age matched lean 
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presence of significant hydronephrosis. However, the albumin/
creatinine ratio was increased at both 10 and 16 weeks in the 
ZDF animal (Table 4). The changes in LV chamber morphology 
and altered myocardial relaxation (Tau) as early as 16 weeks in 
association with evidence of renal impairment suggest that dia-
betes induced cardiac and renal pathophysiology may develop in 
parallel with one another in the ZDF animal.
Nevertheless, only 20% of diabetics with microalbuminuria 
progress to nephropathy and only 20% of those individuals will 
progress to end stage renal disease 20 years after onset of nephrop-
athy.7 In contrast to renal complications, diabetics have a 1.4-fold 
higher chance of developing congestive heart failure.44 It should 
be recognized that renal pathology may not be apparent until 
it is fairly severe, e.g., only after loss of 80–90% of functional 
nephrons. Measurement of urinary glucose is not a good diagnos-
tic indicator of diabetes because glucose does not appear in urine 
until the renal threshold is exceeded. Similarly changes in albu-
minuria and creatininemia probably become apparent only after 
significant loss of renal function. Renal disease may be silent, but 
just as harsh as cardiovascular pathology; the latter may just be 
more easily detected. However, it is clinically evident that once 
the “functional reserve” of the kidney has been exhausted there is 
a compounding affect that severely impacts survival.45
Materials and Methods
Experimental design. All Animal Use Protocols were approved 
by the Institutional Animal Care and Use Committee (IACUC) 
and conform with the Guide for the Care and Use of Laboratory 
Animals, published by the US National Institutes of Health (NIH 
Publication no. 85-23, revised 1996). The Zucker Diabetic Fatty 
rats (ZDF) rat is an inbred leptin receptor-deficient model of 
adult onset type II diabetes displaying insulin resistance, hyper-
insulinemia and hyperglycemia. Male ZDF (fa/fa) and lean con-
trol heterozygous litter mates (LC; fa/?) were obtained at 6 weeks 
of age (~200 g) from Charles River Laboratories (Wilmington, 
MA). All animals were maintained on Purina 5008 rat chow with 
water ad libitum. Animals were housed two to a cage in a 12:12-h 
dark/light cycle controlled room. At the age of 10 weeks, after 
confirming hyperglycemia via tail vein blood samples, the ani-
mals were divided into two experimental groups: (1) lean control 
rats (LC; n = 7) and untreated ZDF rats (n = 7) sacrificed at 16 
weeks of age, and (2) lean control rats (LC; n = 7) and untreated 
ZDF rats (n = 9) sacrificed at 36 weeks of age. These time points 
were chosen as they best correspond to the early (14–17 weeks of 
age) and later stage (24–37 weeks of age) ranges of animal ages 
used in previous studies, focused on either cardiac14-16,23,46 or renal 
pathophysiology.13,17,18,36,41,47 Prior to sacrifice, left ventricular sys-
tolic  and  diastolic  structural  and  functional  parameters  were 
assessed; plasma samples were collected, the heart and kidneys 
were removed, rinsed in ice cold PBS and weighed, and then por-
tions were either snap frozen in liquid nitrogen for biochemical 
analysis or placed in Telley’s fixative for histological analysis.
Left  ventricular  functional  assessment.  As  previously 
described, LV systolic and diastolic pressure and volume func-
tional analysis was performed in anesthetized rats using a high-
time point. However, in this model of type II diabetes it remains 
uncertain as to whether this is an adaptational response to wors-
ening cardiac function or expansion of blood volume due to renal 
impairment as suggested by others.28,29
The difference in LV mass in ZDF rats, compared to LC, is 
an interesting observation. Indeed, changes in LV mass and or 
geometry greatly affect the overall function of the heart, and 
are typically a progressive response to chronic physiologic stress 
such as alterations in cardiac output due to altered hemodynamic 
load on the heart.30 Although overt hypertension was not evi-
dent in these animals (Table 2), wall stiffening (as indicated 
by increased Tau), which commonly occurs in diabetic cardio-
myopathy,  would  necessitate  chamber  dilation.  Regardless  of 
etiology (i.e., volume overload, pressure overload or myocardial 
injury) persistent elevation in ventricular wall stress initiates car-
diac remodeling that results in; (1) initial ventricular dilatation 
to maintain stroke volume and thus cardiac output, (2) subse-
quent cardiac dysfunction due to excessive remodeling, and (3) 
ultimately decompensated heart failure.31 Recent clinical studies 
on left ventricular hypertrophy (LVH) in type II diabetes, based 
on echocardiography, indicate that there are also a significant 
number of normotensive individuals which do not present with 
indication(s) of LVH.32-34 The untreated ZDF animals appear to 
be similar to this clinical phenotype in which there is limited (or 
inadequate) hypertrophy.
Renal morphology and function. The progression of pro-
teinuria in the Zucker diabetic fatty rat has been documented 
before,17,35-37  but  without  parallel  studies  on  cardiac  function. 
Recent studies by Bickel et al.38,39 as well as Maddox and cowork-
ers40 found that, even with the presence of mild changes in glom-
erular morphology in 24-week-old ZDF animals, there was no 
difference in creatinine clearance, compared to age-matched lean 
controls. The albumin to creatinine ratio, an indicator of microal-
buminuria, was significantly different after 24 weeks of age. The 
association between microalbuminuria and cardiovascular risk is 
well established, however only recently has it been recognized as 
having predictive value of heart failure.11 Although we did not 
measure glomerular filtration, we did observe moderate to severe 
hydronephrosis at 36 weeks in ZDF animals. Previous studies 
have  detailed  similar  findings  of  hydronephrosis  in  the  ZDF 
rat,12,41 however, the underlying etiology remains uncertain. Since 
both the LC and ZDF animals presented with this pathology, 
the leptin receptor deficiency is probably not the cause. However, 
Marsh  et  al.12  postulated  an  epigenetic  cause  as  a  potential 
underlying heritable mechanism behind hydronephrosis in these 
animals. Recent work by El Osta et al.42 demonstrated that tem-
porary hyperglycemia induced persistent epigenetic changes in 
the promoter of the nuclear factor kappaB (subunit p65 NFκB) 
which lasted for at least 6 days under subsequent normoglycemic 
conditions. While the ZDF rat is only one of many models of 
diabetes, this same phenomenon of hydronephrosis also occurs in 
the KKay transgenic mouse model of type II diabetes.43
Renal and cardiovascular function in diabetes. While our 
findings indicate that EDV for the 16 week old ZDF animals 
was markedly increased, similar to the findings of Marsh et al.12 
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are  expressed  as  means  ±  SEM  unless  otherwise  noted.  Data   
comparisons  for  pressure/volume  parameters  between  age-
matched LC and ZDF were made by student’s t-test. Renal 
functional measurements were analyzed by repeated measures 
one way analysis of variance. A p-value of ≤0.05 was judged 
significant.
Conclusion
The  findings  herein  indicate  that  changes  in  LV  chamber   
morphology occurred in the untreated ZDF animals as early 
as 16 weeks of age as a diabetes-induced adaptation to main-
tain overall function. Compared to lean controls, excretion of 
urinary albumin, albumin-creatinine ratio and hydronephrosis 
also progressively worsened with age. In summary it appears 
that  both  cardiac  and  renal  complications  are  developing 
in parallel, as there is evidence of progressive structural and   
functional changes in both the heart and kidney, starting as 
early as 16 weeks, without evidence that one precedes or causes 
the other in the ZDF model of type II diabetes.
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fidelity Millar pressure/volume (SPR-838; Millar Instruments, 
Houston, TX) conductance catheter inserted into the LV via the 
right carotid artery.48-50 For calibration, this measurement tech-
nique requires that a small amount (0.1 ml) of 15% saline be 
introduced into the blood volume of the anesthetized animal at 
the end of the experimental protocol as a correction factor for the 
blood-LV tissue interface. Data were analyzed using PVAN 3.5 
software from Millar Instruments.
Assessment of renal structural and functional changes. The 
right kidney was cut along a sagital plane in the hilar region and 
fixed by immersion in Telley’s fixative. Following staining with 
hematoxylin and eosin, hydronephrosis was calculated by criteria 
previously described.12,41 Briefly, kidney sections were assigned a 
value of either; (0) minimal or no spacing between the papilla 
and calyx, (1) definitive but mild calyceal spacing with normal 
papillary shape, (2) calyceal dilatation and compression of the 
papilla, and (3) extreme distension of the calyx, compaction of 
the lateral cortex and severe papillary dilatation.
Urinary  measurements. Animals were individually housed 
in metabolic cages for measurement of twenty-four hour water 
intake and urine production. Urine samples were stored at -80°C 
until assayed for urinary albumin using an ELISA assay (Cayman 
Chemicals, Ann Arbor, MI) and urinary creatinine by a colori-
metric kit assay based on the Jaffe reaction (Bio-Rad, Hercules, 
CA). From these measurements, the albumin to creatinine ratio 
was determined.
Statistics. Statistical analyses were performed with Graphpad 
5.0  software  (Prism  Inc.,  San  Diego,  CA).  All  grouped  data 
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